Jonathan Garnier1, Cloe Magallon2, Jacques Ewald2, Anaïs Palen2, Ugo Marchese2, Jean-Robert Delpero3, Olivier Turrini3. 1. Department of Surgical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009, Marseille, France. garnierj@ipc.unicancer.fr. 2. Department of Surgical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009, Marseille, France. 3. Department of Surgical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, 27 Boulevard Leï Roure, CS 30059, 13273, Marseille Cedex 09, France.
Abstract
PURPOSE: Positive para-aortic lymph nodes (PALN) (station 16) are commonly detected in the final pathologic examination (ranging from 15 to 26%) among patients who undergo upfront pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma. However, after neoadjuvant treatment (NAT) the role of positive PALN as a watershed for surgical resection remains unclear. We aimed to determine the incidence of intraoperative detection of PALN after NAT with FOLFIRINOX for pancreatic head adenocarcinoma and its impact on survival, as our policy was to not resect the tumor in such situations. METHODS: From January 2014 to December 2020, 136 patients with non-metastatic cancer who received neoadjuvant FOLFIRINOX and underwent explorative laparotomy were included. RESULTS: Intraoperative positive PALN were observed in 7 patients (5%). Patients had resectable (n = 5) or locally advanced (n = 2) disease at the time of surgery, but none of them underwent surgical resection. Positive PALN were significantly associated with a lower median number of FOLFIRINOX cycles (4 vs. 6, P = 0.05). There was no significant difference in overall survival between patients with positive loco-regional lymph nodes after resection and patients with non-resection owing to positive PALN (22 versus 16 months, P = 0.16), Overall survival with positive PALN, carcinomatosis, and liver metastasis was 16, 14, and 10 months, respectively (P > 0.05). CONCLUSIONS: Our results suggest that NAT may lower PALN involvement. We have modified our policy, positive PALN after NAT are no longer a contraindication to resection, rather a holistic picture of the disease guides management.
PURPOSE: Positive para-aortic lymph nodes (PALN) (station 16) are commonly detected in the final pathologic examination (ranging from 15 to 26%) among patients who undergo upfront pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma. However, after neoadjuvant treatment (NAT) the role of positive PALN as a watershed for surgical resection remains unclear. We aimed to determine the incidence of intraoperative detection of PALN after NAT with FOLFIRINOX for pancreatic head adenocarcinoma and its impact on survival, as our policy was to not resect the tumor in such situations. METHODS: From January 2014 to December 2020, 136 patients with non-metastatic cancer who received neoadjuvant FOLFIRINOX and underwent explorative laparotomy were included. RESULTS: Intraoperative positive PALN were observed in 7 patients (5%). Patients had resectable (n = 5) or locally advanced (n = 2) disease at the time of surgery, but none of them underwent surgical resection. Positive PALN were significantly associated with a lower median number of FOLFIRINOX cycles (4 vs. 6, P = 0.05). There was no significant difference in overall survival between patients with positive loco-regional lymph nodes after resection and patients with non-resection owing to positive PALN (22 versus 16 months, P = 0.16), Overall survival with positive PALN, carcinomatosis, and liver metastasis was 16, 14, and 10 months, respectively (P > 0.05). CONCLUSIONS: Our results suggest that NAT may lower PALN involvement. We have modified our policy, positive PALN after NAT are no longer a contraindication to resection, rather a holistic picture of the disease guides management.
Authors: M Kayahara; T Nagakawa; H Kobayashi; K Mori; T Nakano; N Kadoya; T Ohta; K Ueno; I Miyazaki Journal: Cancer Date: 1992-10-15 Impact factor: 6.860
Authors: L Schwarz; R M Lupinacci; M Svrcek; M Lesurtel; M Bubenheim; H Vuarnesson; P Balladur; F Paye Journal: Br J Surg Date: 2014-04 Impact factor: 6.939
Authors: T Hackert; W Niesen; U Hinz; C Tjaden; O Strobel; A Ulrich; C W Michalski; M W Büchler Journal: Eur J Surg Oncol Date: 2016-11-09 Impact factor: 4.424
Authors: Theodoros Michelakos; Ilaria Pergolini; Carlos Fernández-Del Castillo; Kim C Honselmann; Lei Cai; Vikram Deshpande; Jennifer Y Wo; David P Ryan; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Janet E Murphy; Ryan D Nipp; Aparna Parikh; Motaz Qadan; Andrew L Warshaw; Theodore S Hong; Keith D Lillemoe; Cristina R Ferrone Journal: Ann Surg Date: 2019-04 Impact factor: 12.969